Resource id #3DrugId:1d00000136resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   


Drug ID: 1d00000136

Drug Name: Atracurium

Generic Names: Artacil (50 mg) | Artacil (25 mg) | Acris (25 mg) | Arium (50 mg) | Tracrium (25 mg) | Atcurium (25 mg) | Acris (10 mg) | Artacil -100 | Arium (25 mg) | Atrelax (25 mg) | Troycurium (25 mg) | Atracurium Besylate Injection | Tracrium

Category: Skeletal Muscle Relaxants

Legal Status: Non Opioid Prescription only drug

OTC: No

Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Recommended Dose: The initial recommended dose is 0.4 to 0.5 mg/kg, given as an intravenous bolus injection.

Recommended In: This medication is a neuromuscular-blocking agent, used as an adjuvant in anesthesia. This medication provides relaxation of skeletal muscles during surgery.

Directions For Use: It comes as a solution for injection to be administered by a healthcare provider.

Storage: Store it at refrigerator (2° to 8°C). Do not freeze it.

Dosage Forms: Injection

Side Effects: General- Allergic reactions.

Heart- Increased/decreased heart rate, low/high blood pressure and flushing.

Respiratory- Wheezing, difficulty in breathing and asthma.

Skin- Redness, itching, rash and hives.

In Case of Overdose: There has been limited experience with overdosage of atracurium besylate . The possibility of iatrogenic overdosage can be minimized by carefully monitoring muscle twitch response to peripheral nerve stimulation. Excessive doses of atracurium besylate can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension. If cardiovascular support is necessary, this should include proper positioning, fluid administration, and the use of vasopressor agents if necessary. The patient†s airway should be assured, with manual or mechanical ventilation maintained as necessary. A longer duration of neuromuscular block may result from overdosage and a peripheral nerve stimulator should be used to monitor recovery. Recovery may be facilitated by administration of an anticholinesterase reversing agent such as neostigmine, edrophonium, or pyridostigmine, in conjunction with an anticholinergic agent such as atropine or glycopyrrolate. The appropriate package inserts should be consulted for prescribing information.

Avoid If: Patient must be ensured with adequate ventilation.

Do not administer this medication into the muscle directly.

Caution should be exercised in patients with history of severe allergic reactions, asthma, heart disease, myasthenia gravis, neuromuscular disease, during pregnancy and lactation.

Drug Interaction: Drugs which may enhance the neuromuscular blocking action of atracurium besylate include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.

The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by atracurium besylate. atracurium besylate should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.



Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main